Welcome to our dedicated page for MeiraGTx Holdings plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
Harris Keith R. reported acquisition or exercise transactions in this Form 4 filing.
MeiraGTx Holdings plc director Harris Keith R. received a grant of 106,441 restricted share units as equity compensation. Each unit represents the right to receive one ordinary share upon settlement. These restricted share units vest in a single installment on the earlier of June 11, 2027 or the day immediately before the company’s 2027 annual shareholder meeting. Following this grant, Harris holds 106,441 restricted share units directly.
MeiraGTx Holdings plc reported results of its annual general meeting held on June 11, 2026. Shareholders representing 75,326,022 ordinary shares, about 81.4% of shares outstanding as of the April 21, 2026 record date, were present or represented by proxy.
Three Class II directors — Ellen Hukkelhoven, Ph.D., Nicole Seligman and Debra Yu, M.D. — were elected to serve until the 2029 annual meeting and until their successors are elected and qualified. Shareholders also approved the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 73,933,288 votes for, 1,029,075 against, and 363,659 abstaining.
PERCEPTIVE ADVISORS LLC reported acquisition or exercise transactions in this Form 4 filing.
MeiraGTx Holdings plc reported a new equity award to a Perceptive Advisors–related entity tied to board service. Perceptive-affiliated holders received 60,000 restricted share units, each convertible into one ordinary share upon settlement. The units vest in a single installment on the earlier of June 11, 2027 or the day before the company’s 2027 annual shareholder meeting, and become settleable when director Ellen Hukkelhoven leaves the board. The filing notes Perceptive Advisors, its master fund, and Joseph Edelman may be deemed to have only an indirect pecuniary interest and each disclaims beneficial ownership beyond that indirect interest. This is a compensation-related equity grant rather than an open-market purchase or sale.
MeiraGTx Holdings plc director Harris Keith R. exercised equity awards to acquire additional stock. He converted 75,000 restricted share units into 75,000 ordinary shares through an exercise or conversion of a derivative security, with no reported purchase price.
Following this transaction, his direct holdings in ordinary shares increased to 200,000 shares. The related derivative position in these 75,000 restricted share units is now shown as fully converted, reflecting a routine compensation-related equity settlement rather than an open-market trade.
MeiraGTx Holdings plc executive Richard Giroux reported a bona fide gift of company shares. The CFO & COO gifted 7,000 Ordinary Shares at a price of $0.0000 per share and now holds 964,530 Ordinary Shares directly. He also reports indirect ownership of 85,000 Ordinary Shares through Aigle Healthcare Partners III LLC and 5,152 Ordinary Shares held by his spouse.
MeiraGTx Holdings plc President & CEO Alexandria Forbes reported an open-market sale of 62,000 Ordinary Shares on May 19, 2026 at a weighted average price of $9.17 per share. The shares were sold in multiple trades between $8.96 and $9.32.
After this transaction, Forbes directly holds 1,387,695 Ordinary Shares. The sale was carried out under a Rule 10b5-1 trading plan that was adopted in advance, indicating the trades were pre-scheduled rather than opportunistic.
MGTX filed a Form 144 notice relating to proposed sales of 62,000 ordinary shares. The filing lists an Incentive Compensation Stock Grant dated 06/07/2018, records a sale dated 03/24/2026 of 62,000 shares, and includes numeric lines showing 459,420 and 568,540 alongside a 05/19/2026 entry.
MeiraGTx Holdings plc chief development officer Penny Renee Fleck reported compensation-related equity grants. She received 100,000 restricted share units, each convertible into one ordinary share upon vesting, and a stock option for 100,000 ordinary shares at an exercise price of $9.97 per share, vesting over several years with final option expiration on May 1, 2036.
MeiraGTx Holdings plc filed an initial insider ownership report for Penny Renee Fleck, who serves as Chief Development Officer. This Form 3 shows no reported transactions, derivative positions, or holdings, indicating a baseline disclosure of her status as a reporting officer without current share activity in this filing.
MeiraGTx Holdings plc reported Q1 2026 results with service revenue of $293,000 and a net loss of $46.3 million, compared with $40.0 million a year earlier. Operating expenses were $41.1 million, driven mainly by research and development and manufacturing costs.
Cash, cash equivalents and restricted cash totaled $73.8 million at March 31, 2026, and management expects liquidity, including an additional $100.0 million public equity raise completed in Q2 2026 and a tax incentive receivable, to fund operations for at least twelve months, including a $25.0 million debt repayment due in June.
The company highlighted several strategic transactions: a new asset purchase agreement with Janssen to reacquire its RPGR retinal gene therapy program for an upfront $25.0 million plus contingent milestones and royalties; a collaboration with Lilly that brought an upfront $75.0 million and potential milestones of over $400.0 million; and a broad AI-enabled neurology collaboration with Hologen, featuring a committed $200.0 million upfront payment (of which $105.0 million had been received by March 31, 2026) and up to an additional $230.0 million in program funding.